Vacina contra câncer de pele entra em fase final de estudo

NOVO TRATAMENTO

Karolina Grabowska/Pexels

[{"selector":"#anim-8a3eac0d-0c6e-4cc1-9d60-1c8fd0eb3288","keyframes":{"opacity":[0,1]},"delay":0,"duration":800,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-0ee92c49-9e02-4317-b477-8baaf2e94655","keyframes":{"transform":["translate3d(-85.14851%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":800,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-2f206b4a-6c82-4322-be03-2b6f05d2dfde","keyframes":{"opacity":[0,1]},"delay":0,"duration":800,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-4e1bfcbe-b28a-459f-8687-0f2fac6a5f26","keyframes":{"transform":["translate3d(-117.97753%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":800,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-be64c779-be00-4dd3-9d7d-64572cd61a53 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(-0.007677237648266555%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] Nataliya Vaitkevich/Pexels A fase 2 de testes de uma vacina contra o câncer de pele, aliada à imunoterapia, demonstrou reduzir o risco de recidiva da doença ou morte em pacientes com melanoma de estágios III ou IV

[{"selector":"#anim-b668ea8c-a057-4fc4-b5c1-7c13124ae8e6","keyframes":{"opacity":[0,1]},"delay":0,"duration":800,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-43d4cf43-ad74-47eb-888a-2cedfe2df599","keyframes":{"transform":["translate3d(-85.14851%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":800,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-208fdef1-b779-452c-8799-3d06571b555c","keyframes":{"opacity":[0,1]},"delay":0,"duration":800,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-8ecbb20e-0322-476f-82e1-1e879bf035c5","keyframes":{"transform":["translate3d(-117.97753%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":800,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-855ed2b9-3fb2-448e-ae83-6845e758efef [data-leaf-element=\"true\"]","keyframes":{"transform":["translate3d(-25.23278046195837%, 0, 0)","translate3d(0%, 0, 0)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] Segundo as farmacêuticas Moderna e MSD, o imunizante utiliza a mesma tecnologia da vacina contra a Covid-19 desenvolvida pela empresa – o uso de RNA mensageiro Roger Brown/Pexels

[{"selector":"#anim-99f93b96-4034-4e29-8bdb-38046f6e8c29","keyframes":{"opacity":[0,1]},"delay":0,"duration":800,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-084e0907-2f46-4434-9132-122853d6ff41","keyframes":{"transform":["translate3d(-85.14851%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":800,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-039348be-69f8-49c6-9887-6990b36d6bab","keyframes":{"opacity":[0,1]},"delay":0,"duration":800,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-942e8e7f-3c0f-44ac-98e3-3ca792582adf","keyframes":{"transform":["translate3d(-117.97753%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":800,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-b4290b16-b7df-43f2-bebc-4cf85ed71240 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(0%, 25%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] O tratamento conjunto se demonstrou 44% mais eficaz em reduzir o risco de recidiva ou morte nos pacientes do que a imunoterapia sozinha Klaus Nielsen/Pexels

Os resultados serão discutidos com as autoridades regulatórias para iniciar a fase 3 do estudo ainda em 2023

[{"selector":"#anim-5e515cde-55dc-4f03-b1ce-558c50a40eac","keyframes":{"opacity":[0,1]},"delay":0,"duration":800,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-4dfed5a9-65d1-4d48-9a85-0a5b21dc86fb","keyframes":{"transform":["translate3d(-85.14851%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":800,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-6c04ad22-660b-4c25-8934-73eca32c2da3","keyframes":{"opacity":[0,1]},"delay":0,"duration":800,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-1a901c25-1f5d-4e39-a187-a7b93f25d432","keyframes":{"transform":["translate3d(-116.609%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":800,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-c7cf85c1-f66a-4717-8323-1ae66beb7ead [data-leaf-element=\"true\"]","keyframes":{"transform":["translate3d(-24.314413109446974%, 0, 0)","translate3d(0%, 0, 0)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] Chokniti Khongchum/Pexels

[{"selector":"#anim-254eafb4-03b3-4671-8203-946109146dc0","keyframes":{"opacity":[0,1]},"delay":0,"duration":800,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-b235e34a-fea2-4bcc-8144-c16129cbab1f","keyframes":{"transform":["translate3d(-85.14851%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":800,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-f679c26f-61d5-4ce6-8a38-fa7b8c58ac02","keyframes":{"opacity":[0,1]},"delay":0,"duration":800,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-d64a1971-1892-4e5b-b899-922598f044a0","keyframes":{"transform":["translate3d(-117.97753%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":800,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-dd8819a6-4cd2-486f-8d95-c5afbcf2108d [data-leaf-element=\"true\"]","keyframes":{"transform":["translate3d(-15.581929043650284%, 0, 0)","translate3d(0%, 0, 0)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] A Moderna pretende iniciar estudos adicionais em melanoma e outras formas de câncer com o objetivo de trazer um tratamento individualizado aos pacientes ThisIsEngineering/Pexels

NOVO TRATAMENTO

Vacina contra câncer de pele tem resultados positivos e vai entrar em fase final de estudo

Os resultados serão discutidos com as autoridades regulatórias para iniciar a fase 3 do estudo ainda em 2023

Leia mais no site da CNN Brasil